Nanobiotix SA

Nanobiotix SA

25.24
EUR
-1.00
(-3.81%)
1.65BMarket Cap
Apr 27Next Earn
Nanobiotix SA
GETTEX:5NR
(Gettex)

Recent

price

25.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
EUR
0.17
0.01
0.02
0.08
0.02
0.1
0.01
0.01
- -
- -
- -
- -
0.81
-0.25
0.62
- -
Revenue per Share
-0.65
-0.65
-0.76
-0.74
-1.2
-1.43
-1.5
-1.55
-2.35
-1.38
-1.35
-1.64
-1.08
-1.44
-0.5
- -
Basic EPS, GAAP
-0.61
-0.46
-0.64
-0.67
-1.19
-1.2
-1.28
-1.35
-1.97
-1.13
-0.87
-1.07
-0.35
-0.43
-0.71
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.11
1
0.3
2.16
1.1
1.09
2.24
0.73
-0.09
2.05
0.77
-0.78
-0.04
-1.39
-1.75
-0.66
Book Value per Share
0.11
1
0.3
2.16
1.1
1.09
2.23
0.72
-0.09
2.05
0.77
-0.78
-0.04
-1.39
-1.75
-0.66
Tangible Book Value per Share
8
8
11
13
14
15
17
20
22
24
35
35
37
47
48
49
Basic Weighted Avg Shares
1
- -
- -
1
- -
2
- -
- -
- -
- -
- -
- -
30
-12
30
- -
Sales/Revenue/Turnover
-284.27
-6,948.91
-4,422.79
-994.29
-6,455.32
-1,402.65
-10,026.59
-25,920.69
-68,792.65
-72,856
-525,780
- -
-89.09
589.08
-36.49
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
2
2
2
2
2
2
1
- -
Depreciation Expense
-5
-5
-8
-10
-17
-22
-26
-30
-51
-34
-47
-57
-40
-68
-24
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-385.69
-7,189.05
-4,404.14
-987.75
-6,403.14
-1,404.31
-10,374.21
-26,159.48
-74,875
-67,180
-470,030
- -
-132.08
586.84
-80.83
- -
Profit Margin (%)
1
11
4
31
16
18
44
31
32
106
56
14
37
3
5
38
Working Capital
1
1
1
2
4
4
4
20
43
44
38
49
46
46
91
75
LT Debt
1
11
3
30
16
17
44
14
-2
70
27
-27
-2
-66
-84
-33
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-91.74
-117.38
-57.06
-74.04
-132.57
-85.27
-104.34
- -
- -
-96.66
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
5
4
32
LT Borrowings
44
89
73
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
48
51
Market Capitalization
197
930
1,647

Working Capital

EUR

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
40
63
123
Cash, Cash Equivalents & STI
29
53
111
Accounts Receivable, Net
2
2
2
Inventories
- -
- -
- -
Total Current Liabilities
63
58
86
Payables & Accruals
19
17
14
ST Debt
5
4
32
Deferred Revenue
36
36
36

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-67.29%
627.11%
28.58%
Free Cash Flow
16.78%
18.53%
66.52%
Net Income, GAAP
13.57%
7.54%
-64.83%
Sales/Revenue/Turnover
- -
- -
-355.32%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-12
2025
- -
- -
30
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.44
2025
- -
- -
-0.5
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Nanobiotix S.A. is an advanced clinical-stage biotechnology company pioneering physics-based nanotherapeutics to revolutionize cancer treatment outcomes. Its primary therapeutic candidate, NBTXR3, is a sterile suspension of hafnium oxide nanoparticles engineered to amplify the efficacy of radiation therapy directly within various solid tumors, including head and neck, soft tissue sarcoma, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancers. The company holds a global strategic partnership with Janssen Pharmaceutica for the development and commercialization of NBTXR3, complementing an existing alliance with LianBio for particular markets in Asia. Established in 2003, Nanobiotix is headquartered in Paris, France, and is listed on both Euronext Paris and Nasdaq.

Company News

  • Voting Rights and Shares Capital of the Company

  • NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma

  • Voting Rights and Shares Capital of the Company

  • Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Time to Sell?

  • Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Still a Buy?

  • NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer

  • NANOBIOTIX Provides First Half 2026 Operational and Financial Update

  • Voting Rights and Shares Capital of the Company

  • Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Receives Average Recommendation of “Moderate Buy” from Analysts

  • NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer

  • NANOBIOTIX to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • Voting Rights and Shares Capital of the Company

  • Voting Rights and Shares Capital of the Company

  • Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

  • Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech

  • Voting Rights and Shares Capital of the Company

  • Nanobiotix Provides First Quarter 2026 Operational and Financial Update

  • Nanobiotix Joins the Euronext Tech Leaders Index

  • NANOBIOTIX Announces Closing of Global Offering

  • NANOBIOTIX Announces Full Exercise of Underwriters' Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million